HC Wainwright Reiterates “Buy” Rating for Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock.

CRBU has been the subject of several other reports. Bank of America dropped their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Citigroup dropped their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has a consensus rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Trading Up 5.2 %

Shares of NASDAQ:CRBU opened at $1.00 on Wednesday. Caribou Biosciences has a 12-month low of $0.95 and a 12-month high of $5.77. The company has a market capitalization of $93.00 million, a PE ratio of -0.61 and a beta of 2.34. The business has a 50 day moving average of $1.30 and a two-hundred day moving average of $1.75.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Equities research analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Centric Wealth Management acquired a new position in shares of Caribou Biosciences in the fourth quarter valued at approximately $27,000. Erste Asset Management GmbH acquired a new position in shares of Caribou Biosciences in the third quarter valued at approximately $28,000. Russell Investments Group Ltd. increased its holdings in shares of Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after purchasing an additional 21,416 shares during the period. MetLife Investment Management LLC increased its holdings in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after purchasing an additional 9,148 shares during the period. Finally, Diametric Capital LP acquired a new position in shares of Caribou Biosciences in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.